Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19 cord blood-derived CAR-NK cells

A preparation of cord blood (CB)-derived natural killer (NK) cells that have been genetically modified and transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-CD19 CB-derived CAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	CAR-NK019 CB anti-CD19 CAR NK Cells NK019 CB CAR NK cells NK019 CB CAR-NK019

anti-CD19 cord blood-derived CAR-NK cells

Search NCI's Drug Dictionary